Only three Austrian companies nominated
Vienna, Austria - May 31, 2010 - Nabriva Therapeutics today announced that it has been selected as a finalist for Red Herring's Europe 100 award, a prestigious list honouring the year’s most promising private technology ventures from the world European business region.
The Red Herring editorial team selected the most innovative companies from a pool of hundreds from across Europe. The nominees are evaluated on both quantitative and qualitative criteria, such as financial performance, technology innovation, quality of management, execution of strategy, and integration into their respective industries.
Dr. David Chiswell, CEO of Nabriva Therapeutics said: “I am delighted that Nabriva has been shortlisted for these awards. Nabriva is at an exciting stage of development with two drug candidates of our pleuromutilin pipeline in clinical trials. This nomination validates the enormous progress Nabriva has made in the last year.”
Finalists for the 2010 edition of the Red Herring 100 Europe award are selected based upon their technological innovation, management strength, market size, investor record, customer acquisition, and financial health. During the several months leading up to the announcement, hundreds of companies in the telecommunications, security, Web 2.0, software, hardware, biotech, and clean tech industries sent in their submissions to qualify for the award.
The Finalists are invited to present their winning strategies at the Red Herring Europe Conference in Paris, May 25-27, 2010. The Top 100 winners will be announced at a special awards ceremony on May 27 at the event.
About Nabriva Therapeutics
Nabriva Therapeutics is a biotechnology company focused on developing a new class of antibiotics for the treatment of serious infections caused by resistant pathogens. Nabriva’s lead systemic product, BC-3781, is being developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria. Extensive phase I data have demonstrated that BC-3781 can achieve therapeutically relevant blood and tissue levels in man with excellent tolerability when administered by either oral or intravenous routes. In addition, Nabriva Therapeutics’ topical pleuromutilin product candidate, BC-7013, is also in clinical phase I. Nabriva Therapeutics has a proven track record in world-class medicinal chemistry, clinical expertise, a seasoned management team and solid IP. Nabriva Therapeutics is located in Vienna, Austria.